Latest Articles
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive
Published: April 12, 2026, 2:35 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK US
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK US
Published: April 12, 2026, 2:25 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK
Published: April 12, 2026, 2:25 p.m.
Strong early data prompts GSK to plan five Phase 3 studies for gynecological cancer ADC - Endpoints News
Strong early data prompts GSK to plan five Phase 3 studies for gynecological cancer ADC Endpoints News
Published: April 12, 2026, 2:10 p.m.
BioNTech's Cancer Candidate Clears Path for FDA Filing - AD HOC NEWS
BioNTech's Cancer Candidate Clears Path for FDA Filing AD HOC NEWS
Published: April 12, 2026, 12:31 p.m.
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive
Published: April 12, 2026, 12:58 a.m.
Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer - Cure Today
Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer Cure Today
Published: April 11, 2026, 9:14 p.m.
Black Women With Endometrial Cancer Completed Treatment More With Peer Support - CancerNetwork
Black Women With Endometrial Cancer Completed Treatment More With Peer Support CancerNetwork
Published: April 11, 2026, 8:04 p.m.
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer OncLive
Published: April 11, 2026, 6:14 p.m.
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer Quiver Quantitative
Published: April 11, 2026, 11:10 a.m.
Link copied to clipboard!